Article result template
I'm a little template short and blank. I link to void and keep hidden out.
2024-11-19T10:00:23+0000
I'm a little template short and blank. I link to void and keep hidden out.
2024-11-19T10:00:23+0000
ResMed reports a significant revenue rise of 9% to $1.22 billion USD in the June quarter, highlighting its strong market position despite concerns over weight loss drugs impacting product demand.
2024-08-05T08:13:42+0100
After an initial negative reaction to the weight-loss drug thematic, ResMed says the trend will boost demand for its products. However, with alcohol consumption amongst GLP-1 patients waning, beverage companies could suffer.
2024-05-08T01:11:22+0100
Explore how GLP-1 drugs like Wegovy, Ozempic, and Mounjaro are reshaping the obesity treatment landscape, boosting market valuations for Novo Nordisk and Eli Lilly, and influencing sectors from healthcare to consumer goods.
2023-11-15T00:54:27+0000